|Systematic (IUPAC) name|
|Molar mass||287.397 g/mol|
Moxazocine (BL-4566) is an opioid analgesic of the benzomorphan family which was never marketed. It acts as a partial agonist or mixed agonist/antagonist of the opioid receptors and binds preferentially to the κ-opioid receptor. Despite its failure to reach the market, clinical studies demonstrated moxazocine to be approximately 10x as potent by weight as morphine as an analgesic.
Reduction of the carbonyl group in oxygenated benzomorphan 1 affords the corresponding alcohol (2). This intermediate is then N-demethylated by means of BrCN. Acylation with cyclopropylcarbonyl chloride gives the amide (3). The alcohol is then converted to the ether by treatment with MeI and base (4). Treatment with LiAlH4 serves to reduce the amide function. Cleavage of the phenolic ether by one of the standard schemes affords moxazocine (6).
- Dictionary of Pharmacological Agents Volume 2. CRC Press. p. 1382. ISBN 978-0-412-46630-4. Retrieved 22 April 2012.
- Hayes AG, Sheehan MJ, Tyers MB (August 1987). "Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists". British Journal of Pharmacology. 91 (4): 823–32. doi:10.1111/j.1476-5381.1987.tb11281.x. PMC . PMID 2822190.
- Dobkin, Allen B; Esposito, Barbara F; Noveck, Robert J; Caruso, Frank S (October 1977). "Moxazocine and morphine in patients with severe postoperative pain". Current Therapeutic Research. 22 (4): 469–478.
- T. A. Montzka and J. D. Matiskella, DE 2517220 Chem. Abstr. 84, 59832k (1976).
- U.S. Patent 5,504,245